Understanding Macrophage Complexity in Metabolic Dysfunction-Associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial Dynamics
Livers · 13.09.2024 · 4 (3) · 455-478
DOI: 10.3390/livers4030033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Livers, online erschienen am 13.09.2024. Verfasst von Forkan Ahamed und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, MS 1018, 3901 Rainbow Boulevard, Kansas City, KS 66160,…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 216 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIDDK NIH HHS, NIH.
Abstract (Originalsprache)
Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses metabolic dysfunction-associated fatty liver (MASL) and metabolic dysfunction-associated steatohepatitis (MASH), with MASH posing a risk of progression to cirrhosis and hepatocellular carcinoma (HCC). The global prevalence of MASLD is estimated at approximately a quarter of the population, with significant healthcare costs and implications for liver transplantation. The pathogenesis of MASLD involves intrahepatic liver cells, extrahepatic components, and immunological aspects, particularly the involvement of macrophages. Hepatic macrophages are a crucial cellular component of the liver and play important roles in liver function, contributing significantly to tissue homeostasis and swift responses during pathophysiological conditions. Recent advancements in technology have revealed the remarkable heterogeneity and plasticity of hepatic macrophage populations and their activation states in MASLD, challenging traditional classification methods like the M1/M2 paradigm and highlighting the coexistence of harmful and beneficial macrophage phenotypes that are dynamically regulated during MASLD progression. This complexity underscores the importance of considering macrophage heterogeneity in therapeutic targeting strategies, including their distinct ontogeny and functional phenotypes. This review provides an overview of macrophage involvement in MASLD progression, combining traditional paradigms with recent insights from single-cell analysis and spatial dynamics. It also addresses unresolved questions and challenges in this area.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, MS 1018, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
ORCID-Profile: Elizabeth Jones, Yuxia Zhang
Förderung
- NCI NIH HHS
- NIDDK NIH HHS
- NIH
Zitieren
APA
Ahamed, F., Eppler, N., Jones, E., & Zhang, Y. (2024). Understanding Macrophage Complexity in Metabolic Dysfunction-Associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial Dynamics. Livers, 4(3), 455-478. https://doi.org/10.3390/livers4030033
Vancouver
Ahamed F, Eppler N, Jones E, Zhang Y. Understanding Macrophage Complexity in Metabolic Dysfunction-Associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial Dynamics. Livers. 2024;4(3):455-478. doi:10.3390/livers4030033
BibTeX
@article{Ahamed2024,
author = {Ahamed, Forkan and Eppler, Natalie and Jones, Elizabeth and Zhang, Yuxia},
title = {Understanding Macrophage Complexity in Metabolic Dysfunction-Associated Steatotic Liver Disease: Transitioning from the M1/M2 Paradigm to Spatial Dynamics},
journal = {Livers},
year = {2024},
volume = {4},
number = {3},
pages = {455--478},
doi = {10.3390/livers4030033}
}
EUVIMED